

Elie Ghanem, MD, Fereidoon M. Jaber, MD, and Javad Parvizi, MD
on

Periprosthetic Infection in a Nutshell

Total joint arthroplasty (TJA) is an effective means of improving function and decreasing morbidity in patients with degenerative arthritis. However, deep periprosthetic infection (PPI) remains one of the major complications of TJA,¹ even though incidence has dropped significantly, from 10% during the early era of joint replacement² to the current rate of approximately 1%^{3,4} after primary TJA and up to 7% after revision surgery.^{5,6} This decrease occurred because of the introduction of laminar flow and body exhaust systems and, more important, the administration of prophylactic antibiotics within 30 to 60 minutes of incision.⁷

Although the incidence of PPI appears small, there are massive economic and psychological burdens associated with this complication given the large number of joint replacements being performed.⁸ Further, the extension of indications to perform TJA in patients with medical comorbidities and immunocompromised status is likely to lead to an increase in PPI incidence. Many challenges are associated with this infection. The major challenge is to correctly diagnose PPI before or during surgery and to implement effective treatment regimens capable of eradicating the inciting organism.

Classification

Patients with infected arthroplasties may present at various times after surgery and have differing symptoms. The type of PPI and time of presentation affect treatment and prognosis.^{9,10} Acute postoperative infections are thought to result from the direct seeding of the organism from the operative field, overlying skin, or postoperative drainage.¹¹ Patients present within 4 to 6 weeks after surgery with acute onset of pain, local signs of infection (erythema, cellulitis, drainage),

Dr. Ghanem is Resident, Dr. Jaber is Visiting Assistant Professor, and Dr. Parvizi is Professor, Rothman Institute of Orthopedics, Thomas Jefferson University, Philadelphia, Pennsylvania.

Requests for reprints: Javad Parvizi, MD, 925 Chestnut St, Philadelphia, PA 19107 (tel, 267-339-3617; fax, 215-503-0580; e-mail, parvj@aol.com).

Am J Orthop. 2007;36(10):520-525. Copyright Quadrant HealthCom Inc. 2007. All rights reserved.

and/or systemic toxicity (fever, chills, night sweats). However, late chronic infections are more commonly encountered and usually develop after the 4- to 6-week threshold,³ which gives adequate time for the inciting organism to proliferate and induce indolent symptoms. The third group is the acute hematogenous infections that result in seeding of the implant by an organism found at a remote site.¹² Patients often report a history of recent dental, genitourinary, or gastrointestinal procedures.⁷

Preoperative Workup History and Physical Examination

A thorough clinical evaluation, including detailed history taking, must be performed before progressing with the diagnostic workup. Presence of a draining sinus tract, fever, chills, and/or a history of persistent postoperative drainage with concomitant painful range of motion can be used to accurately diagnose infection in 25% of cases.¹³ Therefore, a rigorous algorithm consisting of additional preoperative and intraoperative tests must be performed for these patients either to rule out or confirm the presence of PPI.¹⁴

Serologic Tests

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are traditional serologic markers used as part of the diagnostic workup in patients with a possibly infected TJA. An ESR arbitrary cutoff of 30 mm/hr has often been used to denote an abnormal finding indicative of possible PPI.¹⁵ CRP is an acute-phase reactant; plasma levels in healthy people are present in trace amounts undetected by standard laboratory techniques and are often reported as less than 0.5 mg/L.

Many conditions, including inflammatory arthropathies, metastatic disease, and chronic conditions such as renal failure, can lead to elevated ESR.¹⁶ CRP is also nonspecific and can be elevated in several infective and traumatic conditions, including surgery,¹⁷ and in inflammatory diseases, especially rheumatoid arthritis.

After TJA, CRP peaks at 48 hours postoperatively¹⁸ and then returns to normal within 3 weeks.^{19,20} ESR lags behind CRP, peaks during postoperative days 5 to 7, and takes 6 weeks^{19,21} to 3 months²² to return to baseline values.

“...the extension of indications to... patients with medical comorbidities...is likely to lead to an increase in PPI incidence.”



Figure 1. Plain x-rays of an infected total hip arthroplasty show changes specific for periprosthetic infection, including areas of focal osteolysis and periosteal reaction.

Therefore, CRP can detect infection in a joint arthroplasty sooner than ESR can, and earlier detection allows for earlier treatment. In the absence of the confounding factors listed earlier, ESR elevations that persist for more than 3 months after surgery and CRP elevations that persist for more than 3 weeks are cause for alarm about possible PPI.

In a recent retrospective study¹⁵ that included patients with inflammatory disorders, results were similar using ESR of more than 30 mm/hr (sensitivity, 63%; specificity, 55%) and CRP of more than 1 mg/dL (sensitivity, 60%; specificity, 63%) to diagnose PPI in revision total knee arthroplasty (TKA). In an older, prospective study of revision total hip arthroplasty (THA) that excluded patients with inflammatory arthropathy, Spanghel and colleagues²³ concluded that ESR of more than 30 mm/h had sensitivity of 82% and specificity of 85% in determining infection. Compared with ESR, however, CRP of more than 1 mg/dL was a better indicator of infection (sensitivity, 96%; specificity, 92%). Although ESR and CRP are not diagnostic of infection when used individually, Spanghel and colleagues concluded that, when both ESR and CRP are below their respective cutoff values, then PPI can be reliably excluded from the differential.

Another serologic test that has shown promising results is interleukin 6 (IL-6), a cytokine that is produced by monocytes and macrophages and induces the production of acute-phase proteins, including CRP.²⁴ IL-6 levels peak during the first 12 hours after surgery and return to preoperative baseline within 3 days.²⁵ Therefore, serum IL-6 levels can be used to detect early postoperative infections and to monitor treatment response, which is not possible with the other commonly used serologic markers. Di Cesare and colleagues²⁶ showed that a cutoff of 12 pg/mL had adequately high sensitivity (100%), specificity (95%), positive predictive value (PPV, 89%), and negative predictive value (NPV, 100%) to diagnose PPI.

Joint Fluid Analysis

Aspirated joint fluid can be analyzed for cell counts and differentials. Although it is generally accepted that aspirate of a nonreplaced joint with a white blood cell (WBC) count of 50,000 cells/ μ L or more and a polymorphonuclear neutrophil percentage (PMN%) of 75% or more is highly suggestive of

infection,²⁷ these values are not applicable to PPI. In a retrospective study of 440 revision TKAs, investigators identified 86 patients with possible PPI and determined that cutoffs of 2500 cells/mL and 60% PMN yielded sensitivity of 98% and specificity of 95% for the diagnosis of PPI.²⁸

Receiver operating curves were first used by Trampuz and colleagues²⁹ in a prospective study of 133 TKAs, of which 34 were revised for PPI. The optimal cutoffs for fluid cell count (1700 cells/ μ L) and PMN% (65%) were defined, and the areas under the curve were compared. PMN% was a significantly better diagnostic modality than absolute leukocyte count (area under the curve, 0.997 vs 0.96; $P = .02$) and had both higher PPV (94% vs 73%) and higher NPV (99% vs 98%). In a recent study of 168 TJAs, Parvizi and colleagues,¹⁴ using receiver operating curves, found similar cutoffs for fluid WBC count (1760 cells/ μ L) and PMN% (73%). The fluid cell count had slightly higher PPV compared with PMN% (99% vs 96%) and slightly lower NPV (88% vs 91%).

The cutoffs used for fluid cell count and differential in native joints to determine infection are too high and have no clinical application in TJA.¹⁴ From a practical standpoint, leukocyte count of more than 2000 cells/ μ L and PMN% of more than 70% can be used to assess for infection in patients with artificial knee or hip joints.

Joint Fluid Culture

Aspirated fluid can be cultured for aerobic and anaerobic organisms. As demonstrated,³⁰ the PPV of culture fluid can be enhanced by using the test to confirm infection rather than to randomly screen patients. Patients with high clinical suspicion of PPI and negative aspiration culture should be reaspirated, as the sensitivity of the test is increased by repeating the procedure.³⁰

Knowledge of the antibiotics sensitivities and resistance profiles of the culprit organism can facilitate preoperative administration of suitable treatments and allow efficacious antibiotics to be combined with cement. It is generally accepted practice to withhold all oral or intravenous (IV) antibiotics during the 2 weeks before aspiration to maximize culture yield.³⁰

X-Rays

Plain x-rays can disclose important information about the mode of TJA failure (Figure 1). Certain changes, such as focal areas of osteolysis, osteopenia, and endosteal and periosteal reactions, are consistent with PPI,³¹ and early implant loosening points to the possibility of an underlying dormant infection.³² Although these changes can be used to determine PPI, they seldom manifest in infected joint arthroplasties,³³ and therefore the role of x-rays is in ruling out other aseptic etiologies.

Radionuclide Modalities

The technetium-Tc99m (⁹⁹Tc) isotope bone scan, which detects areas of increased metabolic activity is often used




Figure 2. (A) Uptake of both technetium (left) and indium-111 labels (right) in concordant areas around the hip implant indicate an aseptic etiology. (B) There is lack of uptake of technetium (left) and increased uptake of indium-111 labels (right).

by many surgeons as part of the initial workup for PPI. This modality has been reported to have high NPV³⁴ and poor specificity (because of the high rate of false-positives), which allow it an important role in screening and ruling out infection. Indium-111, an isotope used to label leukocytes, is another important test that has produced slightly higher sensitivity (77%) and NPV (95%) compared with bone scan.³⁵

Bone scan and indium-111 have been combined to reduce false-positive cases and improve specificity. The technetium scan is injected into the patient and accumulates in areas of high metabolic activity, including bone turnover, and in areas of increased blood flow.³⁶ Leukocytes are then obtained from the patient, labeled with indium-111, and reinjected to delineate areas of inflammation. Increased uptake of both the technetium and the indium-111 labels indicates that aseptic changes are occurring near the TJA, whereas lack of congruence in spatial distribution (ie, increased uptake with indium-111 but no uptake with technetium) indicates infection (Figures 2A, 2B).³⁷

Some centers are implementing fluorodeoxyglucose positron emission tomography (FDG-PET) as part of the preoperative evaluation for PPI (Figures 3A, 3B). This test detects increased glucose uptake by macrophages and neutrophils, especially in areas of inflammation and infection.¹⁴ Love and colleagues³⁷ noted that combined technetium/indium-111 scans had higher specificity compared with FDG-PET scans, but other centers have reported superior results for PET scans in terms of sensitivity and specificity.^{35,38} In a recent prospective study, Pill and colleagues³⁹ compared FDG-PET with combined technetium/indium-111 in 89 patients with 92 painful THAs, of which 21 cases had confirmed PPI. The authors concluded that FDG-PET has far higher sensitivity (95% vs 50%) compared with technetium/indium-111 and is a useful diagnostic tool, with promising ability in differentiating PPI from aseptic etiologies. However, false-positives still plague FDG-PET, especially in areas of particle-induced inflamma-




Figure 3. (A) Uptake around proximal portion of the total hip arthroplasty indicates aseptic loosening. (B) Involvement of distal aspect of the stem is specific for periprosthetic infection.

tion where macrophages accumulate.⁴⁰ Although FDG-PET has shown adequate sensitivity (90%) and specificity (89%) for diagnosing infection around a THA, its ability to confirm PPI in TKA (specificity, 72%) is far inferior because of the large number of false-positives.⁴¹

Intraoperative Diagnostics

Many thorough preoperative workups fail to reach a conclusive diagnosis of infection. Although isolation of an organism from intraoperative culture remains the gold standard for diagnosing infection,^{11,23} one drawback is that the PPI diagnosis is made 3 to 4 days after surgery. However, surgeons can use a multitude of other intraoperative diagnostic modalities, including frozen section of periprosthetic tissue and gram stain, to either confirm or refute the PPI diagnosis.

Frozen Section

Frozen section of periprosthetic tissue is a useful intraoperative test for PPI diagnosis (Figures 4A, 4B). Acute inflammation, as indicated by more than 5 neutrophils per high-power field, may implicate PPI.²⁸ However, the histologic criteria and neutrophil cutoff values used to diagnose infection have varied among clinicians.⁴²⁻⁴⁴

With 2 early studies, Mirra and colleagues^{44,45} began the clarification of the histologic criteria used to diagnose infection. They documented the presence of more than 5 neutrophils per high-power field in 5 separate high-power fields in samples taken from sites of acute inflammation with confirmed positive cultures. In both original articles, however, histologic analysis was performed under a magnification of x500, which may influence results when applying the criteria to the more commonly used x400 microscope. Lonner and colleagues⁴³ attempted to validate these criteria in a prospective study of 175 consecutive patients. They reported sensitivity and specificity of 84% and 96%, respectively, when implementing the aforementioned recommended criteria using x400 magnifica-




Figure 4. (A) Macrophages and giant cells containing particle debris are found in tissues retrieved around aseptically loose implants. Note absence of neutrophils. (B) Presence of numerous neutrophils indicates acute inflammation.

tion. However, specificity improved to 98% when using the more stringent criteria of more than 10 neutrophils per high-power field in more than 5 high-power fields.

In another prospective study, of 106 TKAs and revision THAs, Athanasou and colleagues⁴⁶ compared histologic criteria (>5 inflammatory cells including neutrophils, lymphocytes, and plasma cells per high-power field in >10 high-power fields) to the gold standard of intraoperative culture, which yielded adequate sensitivity (90%) and specificity (96%). On the other hand, in a large retrospective study of 617 revision TJAs, Pandey and colleagues⁴⁷ considered the presence of 1 inflammatory cell per high-power field in at least 10 fields to be consistent with infection. The histologic criteria that they used were in concordance with a clinical diagnosis of infection in 97.8% of the cases of septic failure.

Gram Stain

Gram stain of periprosthetic tissue samples has had poor results in various studies. Sensitivity has ranged from 15% to 30%, depending on the criteria used as a standard for PPI diagnosis,^{14,23, 48} and therefore it cannot detect infection consistently. Although specificity and PPV, which have ranged from 98% to 100%,^{14,23} can confirm PPI when a smear is found to be positive, gram stain remains an ineffective tool for detecting PPI.

Intraoperative Culture

Isolation of an organism from intraoperative fluid or periprosthetic tissue—the current gold standard—has some shortcomings. False-positive (ie, contaminant) or false-negative intraoperative cultures can occur, and these limit the absolute accuracy of the test.^{14,32} However, the test has high specificity (97%-100%) and high PPV (98%-100%) in confirming PPI.^{14,47,48} Although agreement of culture and PPI diagnosis is excellent, an organism may not be isolated in 10% to 12% of cases of confirmed infection.⁴⁷

The exact number of samples that must be obtained to confirm PPI, while adjusting for false-positives caused by

contamination, has been studied extensively. Atkins and colleagues⁴⁸ constructed a mathematical model based on multiple criteria for infection. This model proposes taking 5 or more samples for accurate diagnosis of PPI. However, for practical purposes, including cost-effectiveness, the authors indicated that use of 3 samples or more can have similar sensitivity (65%) and specificity (99.6%). Similarly, Pandey and colleagues⁴⁷ reported that infection can be confirmed in 89% of cases when an organism is isolated from 3 specimens or more.

Molecular Techniques

Polymerase chain reaction (PCR), which relies on amplification of bacterial DNA, has been used for PPI diagnosis.^{49,50} The major problem with PCR is its excessively high rate of false-positives. Refinements (eg, use of bacteria-specific primers and sequencing) may improve the sensitivity of this test. Although PCR can detect a significant number of infected joint arthroplasties, its diagnostic value is depreciated by its high false-negative rate.⁵¹ However, a recent study applied PCR technology to dry reagent dipsticks, which can detect different pathogens within a few hours.⁵²

During recent years, other molecular techniques, such as microarray, have been tested. Deirmengian and colleagues⁵³ demonstrated that WBCs in the synovial fluid of patients with PPI express a “signature” gene. Among the genes found to be differentially expressed were interleukin 1, chemokine ligands CCL3 and CCL4, and intercellular adhesion ligands ICAM1.

Treatment Modalities

Eradicating infection and maintaining a functional prosthesis and extremity are the primary goals of treatment. Multiple factors, including infection type and patient comorbidity, must be considered when selecting treatment for PPI. Indications for the various treatment techniques vary, and therefore treatment must be tailored to the many confounding factors to produce the most satisfactory results.

Two-Stage Resection Arthroplasty With Delayed Reimplantation

In the United States, the treatment of choice is 2-stage exchange arthroplasty, which involves resection arthroplasty and insertion of an antibiotic-impregnated cement spacer supplemented with 6 weeks of IV antibiotics followed by reimplantation arthroplasty at an appropriate time. Even though a delay of 6 to 8 weeks is used as the threshold for reimplantation, the optimal point for spacer removal remains debatable.⁵⁴ After treatment, resolution of infection is confirmed by clinical assessment, serologic tests (ESR, CRP), and, in some cases, joint aspiration.⁵⁵

Reimplantation with cementless components has shown promising outcomes and infection-free survivorship. Hart and Jones⁵⁶ recently successfully eradicated infection in 88% of infected TKAs by a mean of 4 years after surgery. Similarly, a review of 29 chronically infected TKAs revealed an 83%

treatment success rate.⁵⁷ Resection arthroplasty with delayed reimplantation of 44 infected THAs successfully eradicated infection in 98% of cases at a minimum follow-up of 2 years.⁵⁸ However, with evolving bacterial resistance to newer generation antibiotics, existing treatment protocols for virulent and resistant organisms have been questioned. In a review of 46 TJAs with deep PPI, Volin and colleagues⁵⁹ found similar reinfection rates among methicillin-resistant and non-methicillin-resistant staphylococci. However, TKAs infected with resistant organisms have significantly worse survivorship compared with TKAs infected with less virulent bacteria.⁶⁰

Some investigators have advocated using preformed articulating cement spacers to allow for moderate joint motion and ease of subsequent reimplantation.^{28,61} Emerson and colleagues,⁶² who compared articulating cement spacers and static block spacers in 46 infected TKAs, found similar reinfection rates at 3-year follow-up. Use of articulating spacers (vs static block spacers) allowed patients an additional 16° of range of motion after reimplantation. Another investigator devised articulating spacers made of resected components enveloped by antibiotics-impregnated cement.⁶³ These spacers proved to be as efficacious as others⁶¹ in eradicating infection but had the advantages of improved function and decreased pain after reimplantation.

Single-Stage Exchange Arthroplasty

Single-stage exchange arthroplasty entails resection of components, thorough débridement, and same-stage reimplantation followed by 6 weeks of IV antibiotics.⁶⁴ The rate of recurrent infection has been reasonably similar to that reported in the literature for 2-stage resection arthroplasty.⁶⁴ However, some studies comparing the survivorship of the 2 procedures have shown significantly better results and lower failure rates for 2-stage revision arthroplasty.^{65,66}

Irrigation and Débridement

An infected joint arthroplasty can be successfully managed with débridement and component retention in a select group of cases.⁶⁷ This procedure is recommended for sick, elderly patients who have a well-fixed prosthesis and for whom 2-stage exchange arthroplasty is not feasible.⁶⁸⁻⁷⁰ Success with this intervention has varied according to health status, type of infecting organism, and duration of follow-up.⁷¹⁻⁷³ Recently, Marculescu and colleagues⁷⁴ reported a 40% failure rate at 2-year follow-up of 99 infected TJAs treated with débridement and retention of components. Several risk factors for failure have been identified: presence of sinus tract, old age, and prolonged time between symptom onset and treatment,^{71,74,75} among others. Multiple attempts at débridement and retention of components of infected TKAs can decrease the overall failure rate and preserve components.⁷⁶

Chronic Antibiotics Suppression

Serious comorbidities, poor bone stock, and other situations may preclude use of 2-stage resection arthroplasty, in which

case long-term suppressive antibiotics treatment becomes a viable option.^{75,77} Rao and colleagues⁷⁷ reported favorable results in 86% of 36 infected TJAs at a mean follow-up of 5 years. However, 8% of these patients developed complications (most notably, diarrhea) related to chronic use of antibiotics. Other investigators were able to salvage the prosthesis in a similar percentage of patients (63%-83%) through use of long-term antibiotics.^{78,79} However, another study found very poor short-term survivorship (23%) of 13 infected THAs at a mean follow-up of 3 years.⁸⁰

Authors' Disclosure Statement

The authors report no actual or potential conflict of interest in relation to this article.

References

- Vessely MB, Whaley AL, Harmsen WS, Schleck CD, Berry DJ. Long-term survivorship and failure modes of 1000 cemented condylar total knee arthroplasties. *Clin Orthop*. 2006;(452):28-34.
- Charnley J, Eftekhar N. Postoperative infection in total prosthetic replacement arthroplasty of the hip-joint. With special reference to the bacterial content of the air of the operating room. *Br J Surg*. 1969;56(9):641-649.
- Peersman G, Laskin R, Davis J, Peterson M. Infection in total knee replacement: a retrospective review of 6489 total knee replacements. *Clin Orthop*. 2001;(392):15-23.
- Phillips JE, Crane TP, Noy M, Elliott TS, Grimer RJ. The incidence of deep prosthetic infections in a specialist orthopaedic hospital: a 15-year prospective survey. *J Bone Joint Surg Br*. 2006;88(7):943-948.
- Clohisy JC, Calvert G, Tull F, McDonald D, Maloney WJ. Reasons for revision hip surgery: a retrospective review. *Clin Orthop*. 2004;(429):188-192.
- Hanssen AD, Rand JA. Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. *Instr Course Lect*. 1999;48:111-122.
- Hanssen AD, Osmon DR. The use of prophylactic antimicrobial agents during and after hip arthroplasty. *Clin Orthop*. 1999;(369):124-138.
- Jain NB, Higgins LD, Ozumba D, et al. Trends in epidemiology of knee arthroplasty in the United States, 1990-2000. *Arthritis Rheum*. 2005;52(12):3928-3933.
- Fitzgerald RH Jr, Nolan DR, Ilstrup DM, Van Scoy RE, Washington JA, Coventry MB. Deep wound sepsis following total hip arthroplasty. *J Bone Joint Surg Am*. 1977;59(7):847-855.
- Tsukayama DT, Goldberg VM, Kyle R. Diagnosis and management of infection after total knee arthroplasty. *J Bone Joint Surg Am*. 2003;85(suppl 1):S75-S80.
- Bauer TW, Parvizi J, Kobayashi N, Krebs V. Diagnosis of periprosthetic infection. *J Bone Joint Surg Am*. 2006;88(4):869-882.
- Fulkerson E, Valle CJ, Wise B, Walsh M, Preston C, Di Cesare PE. Antibiotic susceptibility of bacteria infecting total joint arthroplasty sites. *J Bone Joint Surg Am*. 2006;88(6):1231-1237.
- Fitzgerald RH Jr. Diagnosis and management of the infected hip prosthesis. *Orthopedics*. 1995;18(9):833-835.
- Parvizi J, Ghanem E, Menashe S, Barrack RL, Bauer TW. Periprosthetic infection: what are the diagnostic challenges? *J Bone Joint Surg Am*. 2006;88(suppl 4):138-147.
- Bare J, MacDonald SJ, Bourne RB. Preoperative evaluations in revision total knee arthroplasty. *Clin Orthop*. 2006;(446):40-44.
- Sox HC. Decision analysis: a basic clinical skill? *N Engl J Med*. 1987;316(5):271-272.
- Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. *Immunol Res*. 2004;30:261-277.
- Shih LY, Wu JJ, Yang DJ. Erythrocyte sedimentation rate and C-reactive protein values in patients with total hip arthroplasty. *Clin Orthop*. 1987;(225):238-246.
- Larsson S, Thelander U, Friberg S. C-reactive protein (CRP) levels after elective orthopedic surgery. *Clin Orthop*. 1992;(275):237-242.
- White J, Kelly M, Dunsmuir R. C-reactive protein level after total hip and total knee replacement. *J Bone Joint Surg Br*. 1998;80(5):909-911.
- Aalto K, Osterman K, Peltola H, Rasanen J. Changes in erythrocyte sedimentation rate and C-reactive protein after total hip arthroplasty. *Clin Orthop*. 1984;(184):118-120.
- Sanzen L, Carlsson AS. The diagnostic value of C-reactive protein in infected total hip arthroplasties. *J Bone Joint Surg Br*. 1989;71(4):638-641.
- Spanghel MJ, Masri BA, O'Connell JX, Duncan CP. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. *J Bone Joint Surg Am*. 1999;81(5):672-683.
- Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase

- response. *Biochem J*. 1990;265(3):621-636.
25. Kraggsbjerg P, Holmberg H, Vikerfors T. Serum concentrations of interleukin-6, tumour necrosis factor-alpha, and C-reactive protein in patients undergoing major operations. *Eur J Surg*. 1995;161(1):17-22.
 26. Di Cesare PE, Chang E, Preston CF, Liu CJ. Serum interleukin-6 as a marker of periprosthetic infection following total hip and knee arthroplasty. *J Bone Joint Surg Am*. 2005;87(9):1921-1927.
 27. Krey PR, Bailen DA. Synovial fluid leukocytosis. A study of extremes. *Am J Med*. 1979;67(3):436-442.
 28. Fehring TK, McAlister JA Jr. Frozen histologic section as a guide to sepsis in revision joint arthroplasty. *Clin Orthop*. 1994;(304):229-237.
 29. Trampuz A, Hanssen AD, Osmon DR, Mandrekar J, Steckelberg JM, Patel R. Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infection. *Am J Med*. 2004;117(8):556-562.
 30. Barrack RL, Jennings RW, Wolfe MW, Bertot AJ. The value of preoperative aspiration before total knee revision. *Clin Orthop*. 1997;(345):8-16.
 31. Peri AD, Davidson D, Masri BA, Duncan CP. The management of peri-prosthetic infection in total joint arthroplasty. *J Bone Joint Surg Br*. 2006;88(2):149-155.
 32. Della Valle CJ, Zuckerman JD, Di Cesare PE. Periprosthetic sepsis. *Clin Orthop*. 2004;(420):26-31.
 33. Duff GP, Lachiewicz PF, Kelley SS. Aspiration of the knee joint before revision arthroplasty. *Clin Orthop*. 1996;(331):132-139.
 34. Levitsky KA, Hozack WJ, Balderston RA, et al. Evaluation of the painful prosthetic joint. Relative value of bone scan, sedimentation rate, and joint aspiration. *J Arthroplasty*. 1991;6(3):237-244.
 35. Scher DM, Pak K, Lonner JH, Finkel JE, Zuckerman JD, Di Cesare PE. The predictive value of indium-111 leukocyte scans in the diagnosis of infected total hip, knee, or resection arthroplasties. *J Arthroplasty*. 2000;15(3):295-300.
 36. Palestro CJ, Swyer AJ, Kim CK, Goldsmith SJ. Infected knee prosthesis: diagnosis with In-111 leukocyte, Tc-99m sulfur colloid, and Tc-99m MDP imaging. *Radiology*. 1991;179(3):645-648.
 37. Love C, Marwin SE, Tomas MB, et al. Diagnosing infection in the failed joint replacement: a comparison of coincidence detection 18F-FDG and 111In-labeled leukocyte/99mTc-sulfur colloid marrow imaging. *J Nucl Med*. 2004;45(11):1864-1871.
 38. Teller RE, Christie MJ, Martin W, Nance EP, Haas DW. Sequential indium-labeled leukocyte and bone scans to diagnose prosthetic joint infection. *Clin Orthop*. 2000;(373):241-247.
 39. Pill SG, Parvizi J, Tang PH, et al. Comparison of fluorodeoxyglucose positron emission tomography and (111)indium-white blood cell imaging in the diagnosis of periprosthetic infection of the hip. *J Arthroplasty*. 2006;21(6 suppl 2):91-97.
 40. Reinartz P, Mummé T, Hermanns B, et al. Radionuclide imaging of the painful hip arthroplasty: positron-emission tomography versus triple-phase bone scanning. *J Bone Joint Surg Br*. 2005;87(4):465-470.
 41. Zhuang H, Duarte PS, Pourdehnad M, et al. The promising role of 18F-FDG PET in detecting infected lower limb prosthesis implants. *J Nucl Med*. 2001;42(1):44-48.
 42. Feldman DS, Lonner JH, Desai P, Zuckerman JD. The role of intraoperative frozen sections in revision total joint arthroplasty. *J Bone Joint Surg Am*. 1995;77(12):1807-1813.
 43. Lonner JH, Desai P, Di Cesare PE, Steiner G, Zuckerman JD. The reliability of analysis of intraoperative frozen sections for identifying active infection during revision hip or knee arthroplasty. *J Bone Joint Surg Am*. 1996;78(10):1553-1558.
 44. Mirra JM, Amstutz HC, Matos M, Gold R. The pathology of the joint tissues and its clinical relevance in prosthesis failure. *Clin Orthop*. 1976;(117):221-240.
 45. Mirra JM, Marder RA, Amstutz HC. The pathology of failed total joint arthroplasty. *Clin Orthop*. 1982;(170):175-183.
 46. Athanasou NA, Pandey R, de Steiger R, Crook D, Smith PM. Diagnosis of infection by frozen section during revision arthroplasty. *J Bone Joint Surg Br*. 1995;77(1):28-33.
 47. Pandey R, Berendt AR, Athanasou NA. Histological and microbiological findings in non-infected and infected revision arthroplasty tissues. The OSIRIS Collaborative Study Group. *Oxford Skeletal Infection Research and Intervention Service. Arch Orthop Trauma Surg*. 2000;120(10):570-574.
 48. Atkins BL, Athanasou N, Deeks JJ, et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. The OSIRIS Collaborative Study Group. *J Clin Microbiol*. 1998;36(10):2932-2939.
 49. Jannes G, De Vos VD. A review of current and future molecular diagnostic tests for use in the microbiology laboratory. *Methods Mol Biol*. 2006;(345):1-21.
 50. Tarkin IS, Dunman PM, Garvin KL. Improving the treatment of musculoskeletal infections with molecular diagnostics. *Clin Orthop*. 2005;(437):83-88.
 51. Levine MJ, Mariani BA, Tuan RS, Booth RE Jr. Molecular genetic diagnosis of infected total joint arthroplasty. *J Arthroplasty*. 1995;10(1):93-94.
 52. Kalogianni DP, Goura S, Aletras AJ, et al. Dry reagent dipstick test combined with 23S rRNA PCR for molecular diagnosis of bacterial infection in arthroplasty. *Anal Biochem*. 2007;361(2):169-175.
 53. Deirmengian C, Lonner JH, Booth RE Jr. White blood cell gene expression: a new approach toward the study and diagnosis of infection. *Clin Orthop*. 2005;(440):38-44.
 54. Hoad-Reddick DA, Evans CR, Norman P, Stockley I. Is there a role for extended antibiotic therapy in a two-stage revision of the infected knee arthroplasty? *J Bone Joint Surg Br*. 2005;87(2):171-174.
 55. Mont MA, Waldman BJ, Hungerford DS. Evaluation of preoperative cultures before second-stage reimplantation of a total knee prosthesis complicated by infection. A comparison-group study. *J Bone Joint Surg Am*. 2000;82-A(11):1552-1557.
 56. Hart WJ, Jones RS. Two-stage revision of infected total knee replacements using articulating cement spacers and short-term antibiotic therapy. *J Bone Joint Surg Br*. 2006;88(8):1011-1015.
 57. Segawa H, Tsukayama DT, Kyle RF, Becker DA, Gustilo RB. Infection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infections. *J Bone Joint Surg Am*. 1999;81(10):1434-1445.
 58. Charlton WP, Hozack WJ, Teloken MA, Rao R, Bissett GA. Complications associated with reimplantation after girdlestone arthroplasty. *Clin Orthop*. 2003;(407):119-126.
 59. Volin SJ, Hinrichs SH, Garvin KL. Two-stage reimplantation of total joint infections: a comparison of resistant and non-resistant organisms. *Clin Orthop*. 2004;(427):94-100.
 60. Kilgus DJ, Howe DJ, Strang A. Results of periprosthetic hip and knee infections caused by resistant bacteria. *Clin Orthop*. 2002;(404):116-124.
 61. Hofmann AA, Kane KR, Tkach TK, Plaster RL, Camargo MP. Treatment of infected total knee arthroplasty using an articulating spacer. *Clin Orthop*. 1995;(321):45-54.
 62. Emerson RH Jr, Muncie M, Tarbox TR, Higgins LL. Comparison of a static with a mobile spacer in total knee infection. *Clin Orthop*. 2002;(404):132-138.
 63. Evans RP. Successful treatment of total hip and knee infection with articulating antibiotic components: a modified treatment method. *Clin Orthop*. 2004;(427):37-46.
 64. Callaghan JJ, Katz RP, Johnston RC. One-stage revision surgery of the infected hip. A minimum 10-year followup study. *Clin Orthop*. 1999;(369):139-143.
 65. Elson RA. Exchange arthroplasty for infection. Perspectives from the United Kingdom. *Orthop Clin North Am*. 1993;24(4):761-767.
 66. Garvin KL, Fitzgerald RH Jr, Salvati EA, et al. Reconstruction of the infected total hip and knee arthroplasty with gentamicin-impregnated Palacos bone cement. *Instr Course Lect*. 1993;42:293-302.
 67. Bernard L, Hoffmeyer P, Assal M, Vaudaux P, Schrenzel J, Lew D. Trends in the treatment of orthopaedic prosthetic infections. *J Antimicrob Chemother*. 2004;53(2):127-129.
 68. Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. *Clin Infect Dis*. 2001;32(3):419-430.
 69. Morrey BF, Westholm F, Schoifet S, Rand JA, Bryan RS. Long-term results of various treatment options for infected total knee arthroplasty. *Clin Orthop*. 1989;(248):120-128.
 70. Rand JA. Alternatives to reimplantation for salvage of the total knee arthroplasty complicated by infection. *J Bone Joint Surg Am*. 1993;75(2):282-289.
 71. Burger RR, Basch T, Hopson CN. Implant salvage in infected total knee arthroplasty. *Clin Orthop*. 1991;(273):105-112.
 72. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. *J Bone Joint Surg Am*. 1996;78(4):512-523.
 73. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. *Clin Infect Dis*. 1992;14(6):1251-1253.
 74. Marculescu CE, Berbari EF, Hanssen AD, et al. Outcome of prosthetic joint infections treated with débridement and retention of components. *Clin Infect Dis*. 2006;42(4):471-478.
 75. Hartman CW, Garvin KL. Dislocation of the hip after reimplantation for infection: an analysis of risk factors. *Clin Orthop*. 2006;(447):24-27.
 76. Mont MA, Waldman B, Banerjee C, Pacheco IH, Hungerford DS. Multiple irrigation, débridement, and retention of components in infected total knee arthroplasty. *J Arthroplasty*. 1997;12(4):426-433.
 77. Rao N, Crosssett LS, Sinha RK, Le Frock JL. Long-term suppression of infection in total joint arthroplasty. *Clin Orthop*. 2003;(414):55-60.
 78. Goulet JA, Pellicci PM, Brause BD, Salvati EM. Prolonged suppression of infection in total hip arthroplasty. *J Arthroplasty*. 1988;3(2):109-116.
 79. Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. *Clin Infect Dis*. 1998;27(4):711-713.
 80. Tsukayama DT, Wicklund B, Gustilo RB. Suppressing antibiotic therapy in chronic prosthetic joint infections. *Orthopedics*. 1991;14(8):841-844.

This paper will be judged for the Resident Writer's Award.